dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Papadimitriou, C. | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Stathopoulos, G. P. | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Economopoulos, T. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Papadimitriou, C. | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Stathopoulos, G. P. | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Economopoulos, T. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Dimopoulos, M. A. | en |
dc.date.accessioned | 2018-06-22T09:53:05Z | |
dc.date.available | 2018-06-22T09:53:05Z | |
dc.date.issued | 2001 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41656 | |
dc.description.abstract | Dose-dense sequential chemotherapy appears to be a promising approach in the management of patients with operable breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. From February 1995 until September 1997, 49 women with histologically confirmed breast cancer and ≥10 involved axillary nodes were treated postoperatively with three cycles of epirubicin (110 mg/m2) followed by three cycles of paclitaxel (250 mg/m2 in a 3-hour infusion) followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m2, methotrexate 57 mg/m2, fluorouracil 840 mg/m2; E-T-CMF). All cycles were repeated every 2 weeks with G-CSF support. Ovarian ablation with monthly injections of triptorelin for 1 year was performed in premenopausal patients and tamoxifen was prescribed for 5 years to all women with positive receptor status after the completion of chemotherapy. A total of 456 cycles of chemotherapy were administered, 363 (80%) of them at full dose. Forty-seven (96%) patients received all 9 cycles of chemotherapy. Relative dose intensity of epirubicin was 0.98, of paclitaxel 0.97, of cyclophosphamide 0.99, of methotrexate 0.98 and of fluorouracil 0.99. Grade 3-4 toxicities included anemia (8%), leukopenia (8%), peripheral neuropathy (6%), neutropenia (4%), thrombocytopenia (4%), stomatitis (2%), diarrhea (2%), fatigue (2%) and hypersensitivity reaction (2%). Febrile neutropenia occurred in 2 patients. Alopecia was universal. After a median follow-up of 3 years, 11 women (22%) relapsed and 4 (8%) died. The 3-year actuarial disease-free survival rate was 72% and the 3-year overall survival rate 90%. The E-T-CMF regimen is well tolerated, as adjuvant treatment, in patients with operable breast cancer with promising activity and deserves further evaluation in phase III studies. Copyright © 2001 S. Karger AG, Basel. | en |
dc.language.iso | eng | en |
dc.source | Oncology | en |
dc.subject | Article | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Tamoxifen | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast neoplasms | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Cancer survival | en |
dc.subject | Chemotherapy | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Cancer recurrence | en |
dc.subject | Clinical article | en |
dc.subject | Diarrhea | en |
dc.subject | Disease-free survival | en |
dc.subject | Fatigue | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Leukopenia | en |
dc.subject | Neutropenia | en |
dc.subject | Recombinant granulocyte colony stimulating factor | en |
dc.subject | Stomatitis | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Drug tolerability | en |
dc.subject | Treatment outcome | en |
dc.subject | Dose response | en |
dc.subject | Epirubicin | en |
dc.subject | High risk patient | en |
dc.subject | Breast cancer | en |
dc.subject | Histopathology | en |
dc.subject | Risk | en |
dc.subject | Peripheral neuropathy | en |
dc.subject | Paclitaxel | en |
dc.subject | Triptorelin | en |
dc.subject | Hypersensitivity reaction | en |
dc.subject | Anthracycline | en |
dc.subject | Anthracyclines | en |
dc.subject | Adjuvant chemotherapy | en |
dc.subject | Premenopause | en |
dc.title | Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1159/000055321 | |
dc.description.volume | 60 | |
dc.description.issue | 3 | |
dc.description.startingpage | 214 | |
dc.description.endingpage | 220 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 | |
dc.gnosis.orcid | 0000-0002-3286-778X | |